Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Operating Leases (2022 - 2025)

Ovid Therapeutics (OVID) has disclosed Operating Leases for 4 consecutive years, with $12.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 10.23% year-over-year to $12.4 million, compared with a TTM value of $12.4 million through Sep 2025, down 10.23%, and an annual FY2024 reading of $13.4 million, down 9.06% over the prior year.
  • Operating Leases was $12.4 million for Q3 2025 at Ovid Therapeutics, down from $12.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $16.2 million in Q3 2022 and bottomed at $12.4 million in Q3 2025.
  • Average Operating Leases over 4 years is $14.6 million, with a median of $14.8 million recorded in 2023.
  • The sharpest move saw Operating Leases decreased 1.09% in 2023, then decreased 10.23% in 2025.
  • Year by year, Operating Leases stood at $16.0 million in 2022, then dropped by 7.78% to $14.8 million in 2023, then dropped by 9.06% to $13.4 million in 2024, then fell by 7.94% to $12.4 million in 2025.
  • Business Quant data shows Operating Leases for OVID at $12.4 million in Q3 2025, $12.7 million in Q2 2025, and $13.1 million in Q1 2025.